HER2+ Gastric Cancer Market Poised for Significant Expansion Through 2034

The HER2-positive gastric cancer market is poised for significant growth up to 2034, fueled by advancements in targeted treatments and an increasing prevalence of the condition, according to DelveInsight's report titled "HER2+ Gastric Cancer - Market Insight, Epidemiology, and Market Forecast - 2034." This aggressive form of gastric and gastroesophageal junction cancers, marked by excessive HER2 protein expression, impacts roughly 15-20% of patients and is linked to swift advancement and unfavorable results without intervention. Yet, progress in therapies, especially those targeting HER2, has notably enhanced survival rates in recent times.

DelveInsight's comprehensive analysis examines the market in major regions including the US, EU4 (Germany, France, Italy, Spain), the UK, and Japan. It covers disease epidemiology, patient load, and breakdowns by age, gender, and biomarker status, alongside patterns in detection, symptoms, and treatment adoption.

Although HER2-specific treatments such as trastuzumab and trastuzumab deruxtecan (ENHERTU) have established new benchmarks in care, obstacles like resistance, tumor diversity, and insufficient biomarker screening persist. The development pipeline is strong, featuring late-stage candidates like antibody-drug conjugates, dual-targeting agents, and immunotherapy blends.

With heightened awareness of the disease, more biomarker-guided diagnoses, and upcoming introductions of innovative therapies, the sector is expected to expand considerably by 2034, creating avenues for drug developers and healthcare professionals to enhance results for a previously neglected group.

For a sample and insights into the newest developments influencing the HER2-positive gastric cancer market and its future, visit https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Key highlights from the HER2-positive gastric cancer market report include:

• The market across the seven major markets (7MM) hit approximately USD 700 million in 2024, with projections for growth by 2034.
• The US dominated with around USD 300 million in 2024, anticipated to increase.
• The 7MM saw about 211,000 new cases of gastric cancer, including GEJ, in 2024, with rises expected.
• Japan represented nearly 60% of HER2-positive cases, while EU4 and the UK accounted for roughly 25%.
• In the US, men made up 66% of gastric cancer cases in 2024.
• ENHERTU, proven in second-line care, is being assessed for first-line HER2-positive gastric cancer.
• In June 2025, Guardant Health, Inc. (Nasdaq: GH) revealed that its Shield multi-cancer screening test earned Breakthrough Device status from the FDA. This blood-based methylation test aims to detect various cancers, such as bladder, colorectal, esophageal, gastric, liver, lung, ovarian, and pancreatic, in individuals 45 and older at average risk.
• In March 2025, the FDA approved pembrolizumab (KEYTRUDA) combined with trastuzumab and chemotherapy (fluoropyrimidine- and platinum-based) for initial treatment of adults with advanced, inoperable, or spreading HER2-positive gastric or GEJ adenocarcinoma showing PD-L1 with a combined positive score of at least 1 (CPS ≥1).
• In February 2025, AstraZeneca projected data from the Phase Ib/II (NCT04379596, DESTINY-Gastric03) study on metastatic or inoperable HER2-positive gastric cancer, GEJ, and GEA in 2026.
• In February 2025, AstraZeneca expected the start of patient enrollment for ENHERTU (NCT06731478, DESTINY-Gastric05) in first-line advanced or metastatic gastric cancer or GEJ adenocarcinoma in Q1 2025, with results after 2026.
• In a January 2025 update, Jazz Pharmaceuticals forecasted potential approval and introduction of zanidatamab as a frontline therapy for GEA in 2026, plus plans to broaden its strategy for the drug that year.
• AstraZeneca anticipated results from the DESTINY-Gastric04 (NCT04704934) trial on HER2-positive gastric cancer or GEJ adenocarcinoma patients who worsened after trastuzumab-based regimens without further systemic treatment, expected in H2 2025.
• In January 2025, ALX Oncology shared encouraging updated results from the ASPEN-06 Phase II trial at the 2025 ASCO Gastrointestinal Cancers Symposium, showing that their CD47 inhibitor, evorpacept, delivers lasting responses and good tolerability in patients with prior treatment for advanced HER2-positive gastric or GEJ cancer.
• Promising new treatments for HER2-positive gastric cancer comprise ZIIHERA (zanidatamab), Rilvegostomig, HLX22 (AC101), Evorpacept (ALX148), TUKYSA (tucatinib), BAY2927088, AB-201 (GCC2003, HER2 CAR-NK), A166 (Trastuzumab botidotin), MRG002, AIDIXI (disitamab vedotin), BAY2701439, ELVN-002, ARX788, XMT-2056, BL-M07D1, and more.
• Major players in HER2-positive gastric cancer treatment include Roche, Elevar Therapeutic, Bristol-Myers Squibb, Merck, Daiichi Sankyo Inc., Genentech, Bayer, Loxo Oncology, Eli Lilly, Remegen Biosciences, AstraZeneca, Hutchison Medipharma Limited, Jiangsu Alphamab Biopharmaceuticals, LintonPharm, Qilu Pharmaceutical Co., Shanghai Henlius Biotech, Bayer, Bristol-Myers Squibb, Ono Pharmaceutical, Jiangsu HengRui Medicine, Seagen, MacroGenics, Zai Lab, Merck Sharp & Dohme Corp., Eisai Inc., Merus N.V., OncXerna Therapeutics, Innovent Biologics, and others. Notably, Daiichi Sankyo Co., Ltd. (Japan) is a key sponsor in trials for trastuzumab deruxtecan (DS-8201, marketed as ENHERTU), a HER2-directed antibody-drug conjugate that delivers a cytotoxic payload to HER2-expressing cancer cells, causing cell death. Their sponsored trials include DESTINY-Gastric03 (NCT04379596, Phase 1b/2) for metastatic or unresectable HER2-positive gastric or GEJ adenocarcinoma post-trastuzumab progression; DESTINY-Gastric05 (NCT06731478, Phase 3) as first-line therapy with chemotherapy for locally advanced or metastatic cases; and DESTINY-Gastric04 (NCT04704934, Phase 3) versus chemotherapy in patients progressed on trastuzumab-containing regimens. Recent updates include anticipated data readouts from DESTINY-Gastric03 in 2026, first patient dosing for DESTINY-Gastric05 in Q1 2025 with data after 2026, and DESTINY-Gastric04 results in H2 2025, alongside approvals for second-line use based on prior Phase 2 and Phase 3 data demonstrating superior overall survival over chemotherapy.

For deeper details on the HER2-positive gastric cancer market prospects, drug adoption, treatment scenarios, and epidemiological patterns, check out: https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

HER2-positive gastric cancer is a unique biological variant of gastric and gastroesophageal 

junction (GEJ) cancers characterized by excessive or amplified human epidermal growth factor receptor 2 (HER2). HER2 acts as a transmembrane tyrosine kinase receptor crucial for cell growth and differentiation. Overexpression occurs in about 15-20% of cases, more frequently in intestinal-type and GEJ tumors.

This variant tends to be more severe, with worse prognoses than HER2-negative types. Still, recognizing HER2 as a treatment target has revolutionized approaches. Trastuzumab's approval with chemotherapy was a milestone, and trastuzumab deruxtecan (Enhertu) has demonstrated strong results in patients who have undergone prior therapy.

Reliable HER2 assessment via IHC and FISH is essential for treatment choices. Despite progress, challenges like initial resistance, developed resistance, and tumor variability hinder long-term success, highlighting the need for ongoing innovation and combined strategies in HER2-positive gastric cancer care.

Obtain a complimentary sample of the HER2-positive gastric cancer market forecast, size, and share analysis report at: https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

The epidemiology segment provides a summary of past, present, and future patterns in the seven major markets from 2020 to 2034. It identifies influencing factors through various studies and expert opinions. It also delivers a thorough breakdown of the diagnosed patient base and upcoming trends.

HER2-positive gastric cancer epidemiology segmentation: The report presents epidemiological data for 2020-2034 in the 7MM, divided into:

• Overall new cases of gastric cancer (including GEJ)
• Cases by gender for gastric cancer (including GEJ)
• Cases by stage for gastric cancer (including GEJ)
• Overall new cases of HER2-positive gastric cancer (including GEJ)
• Overall new cases of advanced HER2-positive gastric cancer (including GEJ)

The drug adoption section analyzes trends in the uptake of newly introduced and forthcoming therapies for HER2-positive gastric cancer over the study period. It assesses patient acceptance rates, market integration, and commercial success of each treatment, clarifying what promotes or impedes market acceptance.

The therapeutics evaluation emphasizes the HER2-positive gastric cancer medications with the fastest adoption. It explores the reasons behind their quick integration and contrasts their market shares to pinpoint those gaining momentum.

Moreover, the report offers an extensive look at the current pipeline for HER2-positive gastric cancer treatments, including experimental drugs at different development phases. It profiles leading pharma and biotech firms driving targeted therapies and updates on collaborations, takeovers, licensing agreements, and other strategic moves influencing the future of HER2-positive gastric cancer treatments.

Discover how new HER2-positive gastric cancer therapies are adapting to changing patient demographics at: https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

The HER2-positive gastric cancer treatment field has undergone a major shift from standard chemotherapy to targeted and immune therapies. HERCEPTIN's approval for first-line use, followed by KEYTRUDA with trastuzumab and chemotherapy, and ENHERTU for second-line, have greatly enhanced results for HER2-positive gastric and GEJ adenocarcinoma patients. Second-line options were once confined to drugs like paclitaxel or irinotecan, but ENHERTU is now the top choice.

Moving forward, the HER2-positive gastric cancer market is set for consistent expansion through 2034, supported by enhanced biomarker testing, refined patient grouping, and innovations in drugs. Upcoming candidates like Zanidatamab, Rilvegostomig, Evorpacept, and HLX22 aim to fill gaps such as resistance and tumor diversity. These new therapies, from antibody-drug conjugates to bispecifics and immunotherapy mixes, are anticipated to raise care standards and broaden options for patients.

HER2-positive gastric cancer market drivers:

• Approvals and use of targeted drugs like trastuzumab, trastuzumab deruxtecan (ENHERTU), and immune combinations have boosted survival, transforming the treatment scene and fueling market growth.
• More HER2 testing and biomarker-based patient selection allow for timely identification of suitable individuals, enhancing treatment accuracy and enlarging the treatable group.

HER2-positive gastric cancer market barriers:

• Initial and developed resistance to HER2-targeted treatments, plus variations in HER2 levels across tumors, restrict long-term effectiveness and outcomes.
• Even with recent approvals, there's a shortage of uniform third-line or later therapies, leaving a gap and unmet needs for those advancing beyond current drugs.

Scope of the HER2-positive gastric cancer market report:

• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan].
• Key HER2-positive gastric cancer companies: Roche, Elevar Therapeutic, Bristol-Myers Squibb, Merck, Daiichi Sankyo Inc., Genentech, Bayer, Loxo Oncology, Eli Lilly, Remegen Biosciences, AstraZeneca, Hutchison Medipharma Limited, Jiangsu Alphamab Biopharmaceuticals, LintonPharm, Qilu Pharmaceutical Co., Shanghai Henlius Biotech, Bayer, Bristol-Myers Squibb, Ono Pharmaceutical, Jiangsu HengRui Medicine, Seagen, MacroGenics, Zai Lab, Merck Sharp & Dohme Corp., Eisai Inc., Merus N.V., OncXerna Therapeutics, Innovent Biologics, and others.
• Key HER2-positive gastric cancer therapies: ZIIHERA (zanidatamab), Rilvegostomig, HLX22 (AC101), Evorpacept (ALX148), TUKYSA (tucatinib), BAY2927088, AB-201 (GCC2003, HER2 CAR-NK), A166 (Trastuzumab botidotin), MRG002, AIDIXI (disitamab vedotin), BAY2701439, ELVN-002, ARX788, XMT-2056, BL-M07D1, and others.
• HER2-positive gastric cancer therapeutic assessment: Currently available and emerging therapies for HER2-positive gastric cancer.
• HER2-positive gastric cancer market dynamics: Drivers and barriers in the HER2-positive gastric cancer market.
• Competitive intelligence analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies.
• HER2-positive gastric cancer unmet needs, KOL's views, Analyst's views, HER2-positive gastric cancer market access and reimbursement.

To learn more about companies active in the HER2-positive gastric cancer treatment market, visit: https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Table of Contents

1. HER2+ Gastric Cancer Market Report Introduction

2. Executive Summary for HER2+ Gastric Cancer

3. SWOT analysis of HER2+ Gastric Cancer

4. HER2+ Gastric Cancer Patient Share (%) Overview at a Glance

5. HER2+ Gastric Cancer Market Overview at a Glance

6. HER2+ Gastric Cancer Disease Background and Overview

7. HER2+ Gastric Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of HER2+ Gastric Cancer

9. HER2+ Gastric Cancer Current Treatment and Medical Practices

10. HER2+ Gastric Cancer Unmet Needs

11. HER2+ Gastric Cancer Emerging Therapies

12. HER2+ Gastric Cancer Market Outlook

13. Country-Wise HER2+ Gastric Cancer Market Analysis (2020-2034)

14. HER2+ Gastric Cancer Market Access and Reimbursement of Therapies

15. HER2+ Gastric Cancer Market Drivers

16. HER2+ Gastric Cancer Market Barriers

17. HER2+ Gastric Cancer Appendix

18. HER2+ Gastric Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. 

Related report

Her2 Positive Gastric Cancer Epidemiology

DelveInsight’s report, “HER2+ Gastric Cancer—Epidemiology Forecast—2034,” provides a comprehensive analysis of HER2-positive gastric cancer, covering historical trends and projected epidemiology across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), Japan, China, and South Korea. The leading HER2+ Gastric Cancer Companies developing potential therapies include - Merck, Daiichi Sankyo, AstraZeneca, Jazz Pharmaceuticals, BeiGene, Zymeworks, Shanghai Henlius Biotech, AbClon, ALX Oncology, Pfizer, Bayer, Enliven Therapeutics, SystImmune, and others.

HER2 Positive Gastric Cancer Pipeline

DelveInsight’s report, “HER2 Positive Gastric Cancer – Pipeline Insight, 2025,” offers a comprehensive overview of the HER2-positive gastric cancer pipeline, covering more than 20 companies and over 20 pipeline drugs. The report includes detailed profiles of both clinical and nonclinical stage products and provides an in-depth assessment of therapeutics by product type, development stage, route of administration, and molecule type. Additionally, it highlights inactive pipeline products within this therapeutic area. The leading HER2+ Gastric Cancer Companies developing potential therapies include - Merck, Daiichi Sankyo, AstraZeneca, Jazz Pharmaceuticals, BeiGene, Zymeworks, Shanghai Henlius Biotech, AbClon, ALX Oncology, Pfizer, Bayer, Enliven Therapeutics, SystImmune, and others.

Media Contact 

Company Name: DelveInsight Business Research LLP

Contact Person: Abhishek kumar

Email: abhishek@delveinsight.com

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com